We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Cardiovascular Systems Inc (CSII) NPV

Sell:$17.96 Buy:$18.00 Change: $1.18 (6.15%)
Market closed |  Prices as at close on 18 January 2022 | Switch to live prices |
Change: $1.18 (6.15%)
Market closed |  Prices as at close on 18 January 2022 | Switch to live prices |
Change: $1.18 (6.15%)
Market closed |  Prices as at close on 18 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cardiovascular Systems, Inc. is a medical technology company, which is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed patented orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

Contact details

1225 Old Highway 8 NW
United States
+1 (651) 2591600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$777.76 million
Shares in issue:
40.55 million
Health Care Equipment
United States
US dollar

Key personnel

  • Scott Ward
    Chairman of the Board, President, Chief Executive Officer
  • Jeffrey Points
    Chief Financial Officer
  • Rhonda Robb
    Chief Operating Officer
  • Stephen Rempe
    Chief Human Resource Officer
  • John Hastings
    Executive Vice President - Operations and Technology
  • Sandra Sedo
    Chief Compliance Officer
  • David Whitescarver
    Vice President - Corporate Development and Intellectual Property
  • Alexander Rosenstein
    General Counsel, Corporate Secretary
  • Ryan Egeland
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.